MagnetisMM-4
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 120 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody, Gamma-Secretase Inhibitor, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1222
- NCT Identifier
- NCT05090566
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.